NCT06433778View on ClinicalTrials.gov

A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)

CompletedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Von Willebrand Disease (VWD)
Interventions
OTHER

No Intervention

This is a non-interventional study.

Trial Locations (7)

B15 2GW

University Hospitals Birmingham, Birmingham

LS9 7TF

Leeds Teaching Hospital, Leeds

L7 8XP

Liverpool University Hospital, Liverpool

NW3 2QG

Royal Free London, London

W2 1NY

Imperial College Healthcare, London

M13 9WL

Manchester University, Manchester

OX3 9DU

Oxford University Hospital, Oxford

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT06433778 - A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK) | Biotech Hunter | Biotech Hunter